The decision means many Americans without underlying conditions may not have access to updated shots this fall."I think we have to admit to ourselves that America is deeply divided on the policy issue of repeat COVID-19 vaccine doses or boosters,

In an editorial article published in the New England Journal of Medicine, Dr. Vinay Prasad, the newly appointed head of the Center for Biologics Evaluation and research at the FDA, and Dr. Martin Makary, FDA commissioner, explained their plan for how the FDA will evaluate and recommend COVID-19 vaccines going forward.

The VRBPAC meeting comes the week after the World Health Organization (WHO) recommended that members consider using monovalent JN.1- or KP.2-lineage COVID-19 vaccine formulations -- the same as last year's -- with monovalent LP.8.1 lineage as a suitable alternative formulation.